News
FDA resurrects Satsuma's nasal migraine treatment
More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi has been given the go-ahead by the agency.
News
Lilly hit as PBM drops Zepbound, but retains Wegovy
Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.
News
J&J's 'Swiss army knife' drug gets first FDA approval
Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for generalised myasthenia gravis (gMG).
News
GSK "well positioned" to weather pharma tariffs
GSK has said it is not too worried about the impact of potential pharma-specific US tariff rules as it posts a solid set of first-quarter results.
News
AZ backs up threat of manufacturing shift from Europe
AstraZeneca has said it is considering a shift in the production of some medicines from Europe to the US in order to sidestep potential tariffs.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
